Vol. 2 Núm. 1 (2024): Revista Multidisciplinaria Investigación Contemporánea
Ciencias de la Salud- Articulo de Revisión

Complicaciones neurológicas periféricas en pacientes adultos Post-Covid-19, Revisión sistemática

DOI: 10.58995/redlic.ic.v2.n1.a59
Cristian Adrian Celdo Suña
Universidad Católica de Cuenca Sede Azogues
Biografía
Jorge Luis Bermeo León
Universidad Católica de Cuenca Sede Azogues
Biografía

Resumen

Introducción: los cambios neurológicos posteriores al Covid-19 se producen por la migración del virus a través de terminaciones nerviosas, las alteraciones identificadas por exámenes de laboratorio, inmunoglobulinas, estudios de imagen, pruebas neurosensoriales individualizan cada trastorno neurológico según su gravedad. Objetivo: sistematizar datos científicos obtenidos en diferentes publicaciones que evalúen complicaciones neurológicas por Covid-19. Metodología: esta revisión sistemática empleo la guía PRISMA 2020 con criterios de inclusión de PEDro y Oxford, obtenidos de ELSEVIER, Wiley Online Library, PubMed, SciELO, Dialnet, Web of Science, Springer Link u otras revistas digitales usando AND, NOT, OR, u, o. Resultados: de un total de 156 artículos, 62 hacen referencia al sistema nervioso periférico,  33 (43%) corresponden anosmia y 23 (30%)  a disgeusia, como las más frecuentes. Conclusiones: el tratamiento se utiliza específicamente para cada patología con una duración de semanas o meses asociado a rehabilitación farmacológica más fisioterapia.

Descargas

Los datos de descarga todavía no están disponibles.

Referencias

  1. Liotta EM, Batra A, Clark JR, Shlobin NA, Hoffman SC, Orban ZS, et al. Frequent neurologic manifestations and encephalopathy-associated Covid-19. Ann Clin Transl Neurol [Internet]. 2020. https://doi.org/10.1002/ACN3.51210 Q1
  2. Delgado C, Valles M, Delgado A, Yus M, Gómez N, Jorquera M, et al. Cognitive dysfunction associated with COVID-19. J Psychiatr Res [Internet]. 2022 https://doi.org/10.1016/j.jpsyc hires.2022.03.033 Q1
  3. Yus M, Matias JA, Gil L, Gómez N, Polidura C, Jorquera M, et al. Persistent olfactory dysfunction after COVID-19 is associated with reduced perfusion in the frontal lobe. Acta Neurol Scand [Internet]. 2022:194-198. https://doi.org/10.1111/ANE.13627 Q2
  4. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020.https://doi.org/10.1001/JAMANEUROL.2020.1127 Q1
  5. Nalbandian A, Sehgal K, Gupta A, Madhavan M V., McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med 2021 274 [Internet].:601-615. https://doi.org/10.1038/s41591-021-01283-z PMID: 33753937 Q1
  6. Gogia B, Gil A, Rai PK, Fang X. A case of COVID-19 with multiple cranial neuropathies.[cited 2022 Jul 27]. https://doi.org/10.1080/00207454.2020.1869001 Q3
  7. Faghy A, Maden T, Arena R, Copeland R, Owen R, Hodgkins H, et al. COVID-19 patients require multi-disciplinary rehabilitation approaches to address persisting symptom,profiles.2022.https://doi.org/10.1080/17476348.2022.2063843 Q2
  8. Arndal E, Lebech A, Podlekarava D, Mortensen J, Christensen J, Rönsholt F, et al. Olfactory and Gustatory Outcomes Including Health-Related Quality of Life 3-6 and 12 Months after COVID-19:JClinMed[Internet].2022Oct1.https://doi.org/10.3390/JCM11206025 Q2
  9. Costa K, Carnaúba A, Rocha K, Andrade K, Ferreira , Menezes P. Olfactory and taste disorders in COVID-19: a systematic review. Braz J Otorhinolaryngol [Internet]. 2020 Nov1:781-792.https://doi.org/10.1016/J.BJORL.2020.05.008 Q2
  10. Touisserkani SK, Ayatollahi A. Oral Corticosteroid Relieves Post-COVID-19 Anosmia in a 35-Year-Old Patient. Case Rep Otolaryngol. 2020 Aug 8;2020:1-2. https://doi.org/10.1155/2020/5892047 Q2
  11. Lechien J, Chiesa E, Siati D, Horoi M, Le B, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate(COVID-19): [Internet].2020Aug1:2251–61.https://doi.org/10.1007/S00405-020-05965-1 Q1
  12. Premraj L, Kannapadi N V., Briggs J, Seal SM, Battaglini D, Fanning J, et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis. J Neurol Sci. 2022 Mar 15;434. PMID: 35121209 Q2
  13. Anaya J, Rojas M, Salinas L, Rodríguez Y, Roa G, Lozano M, et al. Post-COVID syndrome. A case series and comprehensive review. Autoimmun Rev. 2021 Nov 1;20(11). https://doi.org/10.1016/J.AUTREV.2021.102947 Q1
  14. Huang C, Yeming M, Xingwang M, Lili R, Jianping Z, Yi M, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) [Internet]. 2020Feb15:497-506.https://doi.org/10.1016/S0140-6736(20)30183-5 Q1
  15. Siddiqui R, Mungroo MR, Khan NA. SARS-CoV-2 invasion of the central nervous: a brief review. https://doi.org/101080/2154833120211887677 [Internet]. 2021 Aug 1;49(3):157-163 . https://doi.org/10.1080/21548331.2021.1887677 Q3
  16. Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: Lancet Reg Heal - Eur. 2021 Jul 1;6:100122. https://doi.org/10.1016/J.LANEPE.2021.100122 Q1
  17. Jafari Z, Kolb B, Mohajerani M. Hearing L, Tinnitus, and Dizziness in COVID-19: Can J Neurol Sci [Internet]. 2022 Mar 12:184–95. https://doi.org/10.1017/CJN.2021.63 Q2
  18. Mariños E, Espino P, Rodriguez L, Barreto E. Manifestaciones neurológicas asociadas a COVID-19 en el Hospital Edgardo Rebagliati Martins, Perú. Rev Neuropsiquiatr. 2021;83(4):243–56. https://doi.org/10.20453/rnp.v83i4.3890 Q4
  19. Viola P, Ralli M, Pisani D, Malanga D, Sculco D, Messina L, et al. Tinnitus and equilibrium disorders in COVID-19 patients: Eur Arch Oto-Rhino-Laryngology. 2021 Oct1:3725-3730.https://doi.org/10.1007/S00405-020-06440-7 Q1
  20. Elibol E. Otolaryngological symptoms in Covid-19. Eur Arch Oto-Rhino-Laryngology [Internet].2021Apr:1233-1236.https://doi.org/10.1007/S00405-020-06319-7/TABLES/4 Q1
  21. Sahu T, Mehta A, Ratre Y, Jaiswal A, Vishvakarma N, Bhaskar L, et al. Current understanding of the impact of COVID-19 on gastrointestinal disease: World J Gastroenterol [Internet]. 2021 Feb1:449–69.https://doi.org/10.3748/WJG.V27.I6.449 Q1
  22. Chen R, Wang K, Yu J, Howard D, French L, Chen Z, et al. The Spatial and Cell-Type Distribution of SARS-CoV-2 Receptor ACE2 in the Human and Mouse Brains. Front Neurol. 2021;11:0-3. https://doi.org/10.3389/fneur.2020.573095 Q2
  23. Koyama S, Kondo K, Ueha R, Kashiwadani H, Heinbockel T. Possible Use of Phytochemicals for Recovery from COVID-19-Induced Anosmia and Ageusia. Int J Mol Sci [Internet]. 2021 Aug 2;22(16): https://doi.org/10.3390/IJMS22168912 Q1
  24. Ninchritz E, Soriano M, Mayo M, Calvo C, Martínez P, Saga C, et al. Evaluación subjetiva de las alteraciones del olfato y del gusto: Med Clin (Barc) [Internet]. 2021 Jan 22:61-64. https://doi.org/10.1016/J.MEDCLI.2020.08.004 Q3
  25. Sepúlveda V, Waissbluth S, González C. Anosmia y enfermedad por Coronavirus 2019 (COVID-19): Rev Otorrinolaringol y cirugía cabeza [Internet]. 2020:247-258. Q3
  26. Abdelalim A, Mohamady A, Elsayed R, Elawady M, Ghallab A. Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients:. Am J Otolaryngol - Head Neck Med Surg. 2021 Mar 1. https://doi.org/10.1016/J.AMJOTO.2020.102884 Q1
  27. Rashid R, Zgair A, Al-Ani, Effect of nasal corticosteroid in the treatment of anosmia due to COVID-19: Am J Otolaryngol [Internet]. 2021 Sep 1 ;42(5): https://doi.org/10.1016/J.A MJOTO.2021.103033 Q1
  28. Carrasco A, Vinitzky I, Román C, Vélez A, Morales V, Fernández R, et al. Disgeusia como principal manifestación oral en pacientes con COVID-19 Respiratorias. Odontol Sanmarquina. 2022;25(1):e22064.https://doi.org/10.15381/os.v25i1.22064 Q3
  29. Brola W, Wilski M. Neurological consequences of COVID-19. Pharmacol Reports 2022 746 [Internet].2022Sep30:1208-1222.https://doi.org/10.1007/S43440-022-00424-6 Q3
  30. Heckmann S, Hujoel P, Habiger S, Friess W, Wichmann M, Heckmann J, et al. Zinc gluconate in the treatment of dysgeusia. J Dent Res. 2020 Jan 25:35–8. https://doi.org/10.1177/154405910508400105 Q3
  31. Chen L, Deng C, Chen X, Zhang X, Chen B, Yu H, et al. Ocular manifestations and clinical characteristics of 535 cases of COVID-19 in Wuhan, China: Acta Ophthalmol. 2020 Dec 1:e951-e959 . https://doi.org/10.1111/AOS.14472 PMID: 32421258 Q1
  32. Babaei M, Bayani M, Farzin M, Rasoulinejad S. The Association of Clinical Symptoms and Clinical Conditions with Ophthalmic Manifesting in COVID-19 Patients. Casp J Intern Med. 2022:180-186.https://doi.org/10.22088/CJIM.13.0.180 Q3
  33. Shaikh N, Al Mahdi H, Pai A, Pathare A, Abujaber A, Dsliva A, et al. Ocular manifestations of COVID-19: facts and figures from a tertiary care center. Ann Med. 2022:310-313. https://doi.org/10.1080/07853890.2022.2029554 Q1
  34. Ly-Yang F, Gómez V, Pérez P, González N, Porta J, Santos E. Fotofobia intercrítica en el paciente migrañoso. Propuesta de criterios diagnósticos. Neurología [Internet] .2021Feb13;348-390https://doi.org/10.1016/J.NRL.2020.12.004 Q3
  35. Llorente B, López A, Sánchez R, Gutiérrez C. Protocolo diagnóstico de las manifestaciones crónicas de la COVID-19. Med - Programa Form Médica Contin Acreditado. 2022:3256-3260. https://doi.org/10.1016/j.med.2022.05.007 Q2
  36. Bouza E, Moreno R, Ramos L, GarcíaA, García A, Gómez J, et al. Post-covid syndrome: A reflection and opinion paper. Rev Esp Quimioter. 2021:269-279. https://doi.org/10.37201/req/023.2021 Q3
  37. Pardhan S, Vaughan M, Zhang J, Smith L, Chichger H. Sore eyes as the most significant ocular symptom experienced by people with COVID-19:BMJ Open Ophthalmol. 2020 Nov 30;5(1). https://doi.org/10.1136/BMJOPHTH-2020-000632 Q1
  38. Chern A, Famuyide O, Moonis G, Lalwani K. Sudden Sensorineural Hearing Loss and Covid-19.Otol Neurotol.2021:319-332.https://doi.org/10.1097/mao.0000000000003233 Q2
  39. Joshua T, Ayub A, Wijesinghe P, Nunez D. Hyperbaric Oxygen Therapy for Patients With Sudden Sensorineural Hearing Loss: JAMA Otolaryngol Head Neck Surg [Internet]. 2022 Jan 1:5-11 Q2. https://doi.org/10.1001/JAMAOTO.2021.2685 Q1
  40. Vargas N, Trujillo R, Rodríguez F, Franco R, Martínez-Wbaldo M del C, Jiménez A, et al. Hipoacusia en pacientes con y sin COVID-19 antes y después de la recuperación de los casos positivos. Rev ORL [Internet]. 2022 Apr 4:9-18 https://doi.org/10.14201/ORL.27448 Q2
  41. Gold D, Galetta S. Neuro-ophthalmologic complications of coronavirus disease 2019 (COVID-19). Neurosci Lett [Int ernet]. 2021 Jan 18;742.https://doi.org/10.10 16/J.NEULET.2020.135531 Q2
  42. Beukes E, Ulep A, Eubank T, Manchaiah V. The impact of covid-19 and the pandemic on tinnitus: J Clin Med. 2021;10(13):https://doi.org/10.3390/jcm10132763 Q3
  43. Kartal A, Kılıç M. Tinnitus in patients recovering after COVID-19: observational and cross-sectional study. Eur Arch Oto-Rhino-Laryngology [Internet]. 2022 Jul 6;1-8. https://doi.org/10.1007/S00405-022-07501-9/METRICS Q1
  44. Peramo P, López M, López M. Secuelas médicas de la COVID-19. Med Clin (Barc) [Internet]. 2021 Oct;157(8):388-394.https://doi.org/10.1016/j.medcli.2021.04.023 Q3
  45. Almishaal A. Comparative Study of Audiovestibular Symptoms between Early and Late Variants of COVID-19. Audiol Res [Internet]. 2022 Dec 1;12(6):680-695. https://doi.org/10.3390/AUDIOLRES12060065 Q4
  46. Škunca J, Marić G, Ravlić M, Knežević L, Jerković I, Sušić E, et al. Diplopia, COVID-19: Results from a Cross-Sectional Study in Croatia. 2022;10(9):1-9. https://doi.o rg/10.3390/vaccines10091558 Q1
  47. García J, Balaguer R, Dolores M, Ruescas L. COVID-19 resource centre with information.Otorrinolaringol.2020(January):21.https://doi.org/10.1016/j.otorri.2021.07.001 Q2
  48. Islamoglu Y, Celik B, Kiris M. Facial paralysis as the only symptom of COVID-19: Am J Otolaryngol . 2021 Jul 1;42(4). https://doi.org/10.1016/J.AMJOTO.2021.102956 Q1
  49. Berry MD, Berry PD. Contemporary treatment of sexual dysfunction: reexamining the biopsychosocial model. J Sex Med [Internet]. 2023 Feb 22;10(11):2627-2643. https://doi.org/10.1111/JSM.12273 Q1
  50. AlvaC, Mori N, Pacheco K, Velásquez V, Rivera O, Huerta A, et al. Guía de práctica clínica para el diagnóstico y tratamiento del paciente con SGB. Neurol Argentina [Internet]. 2020 Jan 1;12(1):36-48.https://doi.org/10.1016/J.NEUARG.2019.09.006 Q4
  51. Wijdicks M, Klein C. Guillain-Barré Syndrome. Mayo Clin Proc. 2017 Mar 1;92(3):467-479. https://doi.org/10.1016/J.MAYOCP.2016.12.002 Q1
  52. Guardia MP, Ramírez M, Avilés A, Navarrete I, Rojas A, Mancisidor M. Resultados tras el seguimiento a largo plazo de los pacientes evaluados en una unidad de síncope. Cardiocore [Internet].2019Oct:182-186https://doi.org/10.1016/J.CARCOR.2018.07.003 Q4
  53. Oates C, Turagam M, Musikantow D, Chu E, Shivamurthy P, Lampert J, et al. Syncope and presyncope in patients with COVID-19. Pacing Clin Electrophysiol [Internet].2020Oct1;43(10):1139-1148.https://doi.org/10.1111/PACE.14047 Q2
  54. Zhang X, Ye L, Huang Y, Ding X, The WL, Omar S, et al. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . 2020;(January) PMID: 33276180 Q3
  55. Aldè M, Barozzi S, Di Berardino F, Zuccotti G, Consonni D, Ambrosetti U, et al. Prevalence of symptoms in 1512 COVID-19 patients: Intern Emerg Med [Internet]. 2022 Aug 1:1343-1353. https://doi.org/10.1007/S11739-022-02930-0 Q2
  56. Daker L, Elshafei R, Bahi M, Mohammed A, Erfan R, Gomaa M. Could vertigo be a post-COVID-19 ;J Neurol psychiatry Neurosurg [Internet]. 2023 Dec 1 [cited 2023 Jul 16];59(1). https://doi.org/10.1186/S41983-023-00659-X Q3
  57. Kim C, Jeong H, Shin J. Incidence of idiopathic benign paroxysmal positional vertigo subtype by hospital visit type: experience of a single tertiary referral centre. J Laryngol Otol [Internet]. 2023 Jan 16:57-60.https://doi.org/10.1017/S0022215121003923 Q1
  58. José F, González J, Molina J, Arnau L, Iribarren I, Jabaloyas J, et al. Infección por SARS-CoV-2: implicaciones para la salud sexual y reproductiva. Rev Int Androl [Internet]. 2020 Jul 1;18(3):117. https://doi.org/10.1016/J.ANDROL.2020.06.001 Q3
  59. Garcia A, Collado D, Olivares R, Adsuar C. Aplicación del cuestionario EQ-5D-5L en pacientes que padecen incontinencia urinaria. Actas Urol Esp. 2016 Sep 1;40(7):457–62. https://doi.org/10.1016/j.acuro.2016.01.010 Q3
  60. Patiño A, Sanchez C, Iregui D, Fernández N. Guía vejiga hiperactiva no neurogénica en adultos. Urol Colomb [Internet]. 2016 Jan 1: 25(1):62.e1-62.e15. https://doi.org/10.1016/J.UROCO.2016.02.004 Q4
  61. Emordi V, Lo A, Bisharat M, Malakounides G. COVID-19-Bladder and Bowel Inco ntinence:Clin(Phila)[Internet].2023Aug4;https://doi.org/10.1177/00099228231167844 Q2
  62. Araujo M, Brito L, Pochini A, Ejnisman B, Sartori M, Girão M. Prevalence of Urinary Incontinence in CrossFit Practitioners before and during the COVID-19: Rev Bras Ginecol Obstet[Internet].2021Nov143(11):847-852.https://doi.org/10.1055/S-0041-1739463 Q2
  63. Herrero A, Parra J, Diaz T, Arias M, Muñoz J, del Yerro J, et al. Sleep characteristics in health workers exposed to the COVID-19 pandemic. Sleep Med. 2020 Nov 1;75:388-394. https://doi.org/10.1016/J.SLEEP.2020.08.013 Q1
  64. Tedjasukmana R, Budikayanti A, Islamiyah WR, Witjaksono L, Hakim M. Sleep disturbance in post COVID-19 conditions: Front Neurol [Internet]. 2023 Jan 9;13: https://doi.org/10.3389/FNEUR.2022.1095606 Q2
  65. Kennedy M, Helfand I, Gou R, Gartaganis S, Webb M, Moccia J, et al. Delirium in Older Patients With COVID-19:JAMA Netw open [Internet].2020 Nov 19;3(11):19. https://doi.org/10.1001/JAMA NETWORKOPEN.2020.29540 Q2

Publicado 2024-01-01

Palabras clave

  • Covid-19,
  • anosmia,
  • Post Covid-19,
  • Covid-19 prolongado,
  • SARS,
  • disgeusia,
  • SARS-COV2,
  • Covid-19 de largo plazo,
  • manifestaciones neurológicas
  • ...Más
    Menos

Número

Sección

Ciencias de la Salud- Articulo de Revisión

Cómo citar

Celdo Suña, C. A., & Bermeo León , J. L. (2024). Complicaciones neurológicas periféricas en pacientes adultos Post-Covid-19, Revisión sistemática. Revista Multidisciplinaria Investigación Contemporánea, 2(1), 70-101. https://doi.org/10.58995/redlic.ic.v2.n1.a59